Back to Results
First PageMeta Content
Neuroendocrinology / Peptide hormones / Growth hormones / Growth hormone treatment / Pediatrics / Growth hormone / Lipodystrophy / HIV-associated lipodystrophy / Pituitary adenoma / Endocrine system / Biology / Medicine


PRIOR AUTHORIZATION POLICY Egrifta™ (tesamorelin injection – EMD Serono) To initiate a Coverage Review, Call[removed]OVERVIEW Egrifta is an analog of human growth hormone-releasing factor (GRF), indicated for
Add to Reading List

Document Date: 2013-10-03 14:58:53


Open Document

File Size: 75,36 KB

Share Result on Facebook

City

Rockland / /

Company

EMD Serono Inc / /

Country

United States / /

Event

Person Communication and Meetings / /

Facility

National Institute of Mental Health / Massachusetts General Hospital / National Library of Medicine / /

IndustryTerm

treatment of HIV / /

MedicalCondition

HIV infection / HIV-associated lipodystrophy / lipodystrophy / HIV / AIDS / head trauma / hypersensitivity / hypopituitarism / G. HIV lipodystrophy / infectious disease / pituitary tumor / /

MedicalTreatment

surgery / /

Organization

US Department of Health and Human Services / AIDS Research & Treatment Center of the Treasure Coast / Massachusetts General Hospital / Food and Drug Administration / National Institute of Mental Health / /

Person

Paul B. Growth / /

/

Position

physician / Mechanic / /

Product

Egrifta™ injection / mannitol / /

ProvinceOrState

Massachusetts / /

URL

http /

SocialTag